From 587b7f16cdac505a5c15f27084a247cf3763331f Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 13 Apr 2026 04:24:22 +0000 Subject: [PATCH] vida: extract claims from 2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes - Source: inbox/queue/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes.md - Domain: health - Claims: 1, Entities: 1 - Enrichments: 0 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...-weight-maintenance-post-glp1-cessation.md | 20 +++++++++++++++++++ entities/health/omada-health.md | 12 +++++++++++ 2 files changed, 32 insertions(+) create mode 100644 domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md create mode 100644 entities/health/omada-health.md diff --git a/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md b/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md new file mode 100644 index 000000000..2769f0ed0 --- /dev/null +++ b/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md @@ -0,0 +1,20 @@ +--- +type: claim +domain: health +description: "Omada's high-touch program shows 63% of members maintaining or continuing weight loss 12 months after GLP-1 discontinuation, with 0.8% average weight change versus 6-7% regain in unassisted cessation" +confidence: experimental +source: Omada Health internal analysis (n=1,124), presented ObesityWeek 2025, not peer-reviewed +created: 2026-04-13 +title: Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement +agent: vida +scope: causal +sourcer: Omada Health +--- + +# Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement + +The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1 benefits revert within 1-2 years of stopping medication, suggesting continuous delivery is required. However, Omada Health's Enhanced GLP-1 Care Track analysis challenges this categorical claim. Among 1,124 members who discontinued GLP-1s, 63% maintained or continued losing weight 12 months post-cessation, with an average weight change of just 0.8% compared to the 6-7% average regain seen in unassisted cessation. This represents a dramatic divergence from expected rebound patterns. + +The program combines high-touch care teams, dose titration education, side effect management, nutrition guidance, exercise specialists for muscle preservation, and access barrier navigation. Members who persisted through 24 weeks achieved 12.1% body weight loss versus 7.4% for discontinuers (64% relative increase), and 12-month persisters averaged 18.4% weight loss versus 11.9% in real-world comparators. + +Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window. diff --git a/entities/health/omada-health.md b/entities/health/omada-health.md new file mode 100644 index 000000000..f1226056a --- /dev/null +++ b/entities/health/omada-health.md @@ -0,0 +1,12 @@ +# Omada Health + +**Type:** Digital health company +**Focus:** Employer-sponsored chronic condition management programs +**Key Product:** Enhanced GLP-1 Care Track with behavioral wraparound + +## Overview +Omada Health operates digital health programs for chronic condition management, primarily distributed through employer-sponsored benefits. Their Enhanced GLP-1 Care Track combines medication support with high-touch behavioral interventions including care teams, dose titration education, side effect management, nutrition guidance, exercise specialists, and access barrier navigation. + +## Timeline +- **2025-01-01** — Internal analysis (n=1,124) shows 94% GLP-1 persistence at 12 weeks vs. 42-80% industry range, and 63% of discontinuers maintaining or continuing weight loss 12 months post-cessation +- **2025-10-XX** — Presented post-discontinuation outcomes at ObesityWeek 2025 (peer-reviewed publication pending as of April 2026) \ No newline at end of file